Efficacy of Functional Remediation on Cognitive and Psychosocial Functioning in Patients with Bipolar Disorder: Study Protocol for a Randomized Controlled Study.

bipolar disorder cognition cognitive enhancement cognitive remediation functional remediation functioning psychological therapy psychosocial interventions

Journal

Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646

Informations de publication

Date de publication:
24 Apr 2023
Historique:
received: 22 03 2023
revised: 17 04 2023
accepted: 20 04 2023
medline: 27 5 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: epublish

Résumé

Neurocognitive impairment is a prominent characteristic of bipolar disorder (BD), linked with poor psychosocial functioning. This study's purpose is to evaluate the effectiveness of functional remediation (FR) in enhancing neurocognitive dysfunctions in a sample of remitted patients with diagnosis of BD in comparison to treatment as usual-TAU. To quantify the neurocognitive damage, the Brief Assessment of Cognition in Affective Disorders (BAC-A) will be used, and the overall psychosocial functioning will be measured with the Functioning Assessment Short Test-FAST. The randomized, rater-blinded, controlled study will include two arms (1:1) encompassing 54 outpatients with diagnosis of BD-I and BD-II, as defined by the DSM-5 criteria. In the experimental phase, remitted patients aged 18-55 years will be involved. At the baseline, at the end of intervention and at the 6-month follow-up, patients will be evaluated using clinical scales (Young Mania Rating Scale (Y-MRS) and Hamilton Depression Rating Scale (HAM-D)). Neurocognitive measurements and psychosocial functioning will be valued, respectively, with BAC-A and FAST. The primary expected outcome is that following FR intervention, patients will exhibit improved cognitive abilities and psychosocial outcomes compared to the participants in the TAU group. It is now recognized that neurocognitive deficits are potential predictors of functional outcome in patients with BD. In recent years, there has been a growing interest in the implementation of interventions that, in addition to symptomatic remission, are also aimed at neurocognitive dysfunctions in order to achieve a recovery of psychosocial functioning.

Sections du résumé

BACKGROUND BACKGROUND
Neurocognitive impairment is a prominent characteristic of bipolar disorder (BD), linked with poor psychosocial functioning. This study's purpose is to evaluate the effectiveness of functional remediation (FR) in enhancing neurocognitive dysfunctions in a sample of remitted patients with diagnosis of BD in comparison to treatment as usual-TAU. To quantify the neurocognitive damage, the Brief Assessment of Cognition in Affective Disorders (BAC-A) will be used, and the overall psychosocial functioning will be measured with the Functioning Assessment Short Test-FAST.
METHODS METHODS
The randomized, rater-blinded, controlled study will include two arms (1:1) encompassing 54 outpatients with diagnosis of BD-I and BD-II, as defined by the DSM-5 criteria. In the experimental phase, remitted patients aged 18-55 years will be involved. At the baseline, at the end of intervention and at the 6-month follow-up, patients will be evaluated using clinical scales (Young Mania Rating Scale (Y-MRS) and Hamilton Depression Rating Scale (HAM-D)). Neurocognitive measurements and psychosocial functioning will be valued, respectively, with BAC-A and FAST.
DISCUSSION CONCLUSIONS
The primary expected outcome is that following FR intervention, patients will exhibit improved cognitive abilities and psychosocial outcomes compared to the participants in the TAU group. It is now recognized that neurocognitive deficits are potential predictors of functional outcome in patients with BD. In recent years, there has been a growing interest in the implementation of interventions that, in addition to symptomatic remission, are also aimed at neurocognitive dysfunctions in order to achieve a recovery of psychosocial functioning.

Identifiants

pubmed: 37239180
pii: brainsci13050708
doi: 10.3390/brainsci13050708
pmc: PMC10216230
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Front Psychiatry. 2018 Nov 29;9:641
pubmed: 30555363
Psychol Med. 2023 Feb;53(3):936-944
pubmed: 34140055
Bipolar Disord. 2017 Mar;19(2):146-153
pubmed: 28421717
Bipolar Disord. 2022 Mar;24(2):115-136
pubmed: 34978124
Acta Psychiatr Scand Suppl. 2007;(434):17-26
pubmed: 17688459
Bipolar Disord. 2020 May;22(3):305-306
pubmed: 31965705
J Affect Disord. 2014 Sep;166:86-92
pubmed: 25012414
Aust N Z J Psychiatry. 2019 Dec;53(12):1148-1150
pubmed: 31516027
Clin Pract Epidemiol Ment Health. 2011;7:112-6
pubmed: 21687565
Bipolar Disord. 2018 Mar;20(2):97-170
pubmed: 29536616
N Engl J Med. 2020 Jul 2;383(1):58-66
pubmed: 32609982
Schizophrenia (Heidelb). 2022 Oct 20;8(1):84
pubmed: 36261468
J Affect Disord. 2014 Mar;156:46-55
pubmed: 24439829
Epidemiol Psychiatr Sci. 2013 Jun;22(2):187-94
pubmed: 23089135
Schizophr Res. 2004 Jun 1;68(2-3):283-97
pubmed: 15099610
Bipolar Disord. 2018 May;20(3):228-237
pubmed: 29121444
J Affect Disord. 2020 Aug 1;273:576-585
pubmed: 32560956
Mol Psychiatry. 2018 Apr;23(4):932-942
pubmed: 28461699
Mult Scler. 2015 Mar;21(3):263-81
pubmed: 25623244
Front Neurol. 2020 Aug 21;11:851
pubmed: 32973654
Int J Neuropsychopharmacol. 2019 Aug 1;22(8):467-477
pubmed: 31093646
Eur Neuropsychopharmacol. 2015 Feb;25(2):257-64
pubmed: 24906790
J Affect Disord. 2017 Aug 1;217:210-217
pubmed: 28427032
Bipolar Disord. 2017 Dec;19(8):614-626
pubmed: 28895274
Front Psychiatry. 2021 Jul 09;12:649737
pubmed: 34305668
Int J Bipolar Disord. 2017 Dec;5(1):8
pubmed: 28168631
Hum Brain Mapp. 2022 Jan;43(1):56-82
pubmed: 32725849
CNS Neurol Disord Drug Targets. 2015;14(10):1255-9
pubmed: 26556085
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Lancet. 2016 Apr 9;387(10027):1561-1572
pubmed: 26388529
Psychol Med. 2017 Dec;47(16):2892-2905
pubmed: 28587689
J Affect Disord. 2016 Apr;194:9-15
pubmed: 26800305
Psychol Med. 2022 Mar 08;:1-11
pubmed: 35257646
JAMA Psychiatry. 2021 Aug 1;78(8):848-858
pubmed: 33877289
J Affect Disord. 2019 Jun 1;252:245-252
pubmed: 30991252
Bipolar Disord. 2021 Mar;23(2):196-208
pubmed: 32583630
J Affect Disord. 2017 Feb;209:71-79
pubmed: 27888723
CNS Neurosci Ther. 2010 Oct;16(5):298-307
pubmed: 19895584
Bipolar Disord. 2004 Jun;6(3):224-32
pubmed: 15117401
J Int Neuropsychol Soc. 2017 Aug;23(7):584-593
pubmed: 28762320
Clin Epidemiol. 2021 Oct 29;13:1039-1049
pubmed: 34744458
Bipolar Disord. 2020 Feb;22(1):28-37
pubmed: 31541587
Psychol Med. 2015 Jan;45(2):381-94
pubmed: 25065268
Behav Neurol. 2012;25(4):341-9
pubmed: 22713400
Postgrad Med. 2010 Nov;122(6):107-16
pubmed: 21084787
Br J Psychiatry. 2016 Jan;208(1):87-93
pubmed: 26541692
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Affect Disord. 2010 Dec;127(1-3):71-6
pubmed: 20538343
J Affect Disord. 2019 Mar 1;246:252-261
pubmed: 30590288
Schizophr Bull. 2010 Jan;36(1):36-42
pubmed: 19776206
Am J Psychiatry. 2013 Aug;170(8):852-9
pubmed: 23511717
Arch Gen Psychiatry. 2011 Mar;68(3):241-51
pubmed: 21383262
Psychother Psychosom. 2012;81(4):250-2
pubmed: 22678229
J Affect Disord. 2016 Nov 15;205:378-386
pubmed: 27573491
World Psychiatry. 2016 Oct;15(3):288-289
pubmed: 27717267
Nat Rev Dis Primers. 2018 Mar 08;4:18008
pubmed: 29516993
J Affect Disord. 2016 Jul 1;198:32-8
pubmed: 26998794
Acta Psychiatr Scand. 2021 Apr;143(4):281-283
pubmed: 33720387
Bipolar Disord. 2019 Nov;21(7):621-633
pubmed: 31025470
J Clin Psychiatry. 2017 Nov/Dec;78(9):e1242-e1249
pubmed: 29045770
Bipolar Disord. 2020 May;22(3):216-230
pubmed: 31610086
Eur Psychiatry. 2022 Sep 05;65(1):e57
pubmed: 36059103
J Affect Disord. 2013 Dec;151(3):1003-8
pubmed: 24099884
Int J Bipolar Disord. 2021 May 27;9(1):17
pubmed: 34046710
J Clin Psychiatry. 2015 Mar;76(3):e342-50
pubmed: 25830456
Acta Psychiatr Scand. 2018 Aug;138(2):145-154
pubmed: 29726004
Int J Environ Res Public Health. 2020 May 12;17(10):
pubmed: 32408561
Psychol Med. 2022 Jan;52(2):314-322
pubmed: 32539879
Psychiatry Res. 2011 Oct 30;189(3):379-84
pubmed: 21620484
Psychol Med. 2017 Jul;47(10):1848-1864
pubmed: 28241891
Psychol Med. 2022 Aug 08;:1-11
pubmed: 36047035
Eur Neuropsychopharmacol. 2016 Aug;26(8):1338-47
pubmed: 27139077
Schizophr Bull. 2016 Jul;42 Suppl 1:S90-4
pubmed: 27460622
Br J Clin Psychol. 2022 Mar;61(1):37-57
pubmed: 34291465
J Affect Disord. 2018 Dec 1;241:505-513
pubmed: 30149339
Acta Psychiatr Scand. 2013 Sep;128(3):149-62
pubmed: 23617548
Schizophr Bull. 2021 Jul 8;47(4):997-1006
pubmed: 33772310
Brain Sci. 2023 Feb 14;13(2):
pubmed: 36831863
Bipolar Disord. 2020 May;22(3):303-304
pubmed: 31900991

Auteurs

Vivian Accardo (V)

Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, 25123 Brescia, Italy.

Stefano Barlati (S)

Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, 25123 Brescia, Italy.
Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.

Anna Ceraso (A)

Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, 25123 Brescia, Italy.

Gabriele Nibbio (G)

Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.

Eduard Vieta (E)

Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, 08036 Barcelona, Spain.

Antonio Vita (A)

Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, 25123 Brescia, Italy.
Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.

Classifications MeSH